This information is intended for healthcare professionals based in Belgium and Luxembourg.
If you are not a healthcare professional, click here

Opdivo_Yervoy_Logo Opdivo_Yervoy_Logo Opdivo_Logo Opdivo_Chemotherapy_Logo
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Neoadjuvant NSCLC Metastatic NSCLC Mesothelioma
Renal Cell Carcinoma Urothelial cancer
Renal Cell Carcinoma Urothelial cancer
Advanced MelanomaAdjuvant Melanoma
Adjuvant esophageal (EC or GEJC) 1L adenocarcinoma upper GI 1L or 2L esophageal squamous cell carcinoma (ESCC)
Head & Neck
Hodgkin Lymphoma

WELCOME TO YOUR I-O PORTAL

Your portal with up-to-date educational resources & practical tools to support you in treating your patients with OPDIVO and YERVOY. Select a cancer type.

What’s new ?

Opdivo + CT now
reimbursed in 1L mUC

OPDUALAG reimbursed in 1L advanced melanoma with tumor cell PD-L1 < 1%

Prof. Reck & Prof. Dooms on CheckMate 9LA update at 5 years

Bristol Myers Squibb

Type of Cancers

Thoracic

Melanoma

Head & Neck

Genitourinary
(GU)

Gastro-intestinal (GI)

Hodgkin Lymphoma

Are you pharmacist?
Click here

Are you pathologist?
Click here

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.